211At-CD45 Adds a New Radiobiologic Layer to Transplant Conditioning
First-in-human data now place 211At-CD45 radioimmunotherapy inside the transplant-conditioning conversation for adults with high-risk hematologic malignancies. In this two-stage dose-finding study, a single infusion of astatine-211–labeled anti-CD45 monoclonal antibody was given before nonmyeloablative conditioning with fludarabine and low-dose total body irradiation, followed by allogeneic hematopoietic cell transplantation from HLA-matched or single-allele-mismatched donors. The cohort included 45 adults between 38 and 74 years of age, all facing a high relapse risk from myeloid malignancies or acute leukemia.
The rationale is clinically straightforward. CD45 is broadly expressed across hematopoietic cells, including malignant cells in many leukemias, which makes it an attractive target for delivering radiation directly to marrow and blood compartment disease while limiting spillover into surrounding tissues. Astatine-211 is an alpha emitter, and alpha particles deposit dense energy over a very short path length. In practical terms, that means powerful cytotoxicity where the antibody lands, with a biologic profile that is very different from conventional external-beam radiation or beta-emitting radioimmunotherapy.
One patient’s liver toxicity defined the ceiling.
Dose Escalation, Liver Toxicity, and the Maximum Tolerated Dose
Seventeen patients entered stage I and received doses ranging from 85 to 591 μCi/kg. The patient treated at 591 μCi/kg developed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), which established 500 μCi/kg as the protocol-defined maximum tolerated dose and pushed stage II forward at that dose in 28 additional patients. The dose-finding result matters because it shows how tightly the therapeutic window is being negotiated when a highly potent alpha-emitting construct is layered onto transplant conditioning.
The liver signal is biologically plausible. Sinusoidal endothelial injury is a known vulnerability during transplant preparation, and it can be amplified when targeted radiation adds focal damage to hepatobiliary microvasculature. The study did not frame the toxicity as a systemic inflammatory syndrome or generalized marrow failure; rather, the limiting event was specific and anatomically coherent, which is exactly the kind of signal that shapes next-step development for a radiopharmaceutical platform.
Infusion reactions were mild. Hematopoietic recovery was not delayed, donor chimerism was not impaired, and graft-versus-host disease rates were not increased. Those three observations give the regimen a clinically useful profile: the added radiobiologic intensification did not derail the transplant mechanics that determine whether a patient engrafts and stabilizes after conditioning.
Early Cytotoxic Activity Appeared Before Standard Conditioning Began
Among the 13 patients who had circulating blasts at baseline, 12 cleared their blasts before fludarabine and total body irradiation were started. That is the sharpest efficacy signal in the report, because it shows immediate antitumor activity before the conventional conditioning backbone had even begun doing its work. In a disease setting where relapse drives failure after allogeneic HCT, pre-transplant cytoreduction can matter as much as post-transplant immune pressure, especially when disease burden is high at the time of conditioning.
The finding is also mechanistically important. CD45-directed alpha therapy is designed to place lethal radiation directly onto hematopoietic and leukemic targets. Clearing circulating blasts before the standard transplant regimen starts suggests the construct is not merely a theoretical intensifier but an active cytotoxic bridge into transplant. For patients with aggressive disease, that kind of rapid compartmental clearance may reduce the burden of residual malignant cells that can seed relapse after engraftment.
Stage II revealed a more complex safety picture. Six patients developed VOD/SOS, and all six were receiving sirolimus as part of graft-versus-host disease prophylaxis for unrelated donor transplantation. The overlap does not prove causation, but it does raise a clinically relevant caution signal, because sirolimus has long been associated with endothelial and hepatic toxicity in transplant settings. When combined with targeted alpha radiation and the endothelial stress of conditioning, the liver may become the first organ to declare the regimen’s limits.
Survival Readouts Support Phase II Development, But the Hepatic Signal Cannot Be Ignored
At 1 year, estimated relapse-free survival was 42% with a 95% confidence interval of 28% to 56%, and estimated overall survival was 49% with a 95% confidence interval of 34% to 62%. These estimates are early and come from a dose-finding study rather than a randomized comparison, so they cannot establish superiority over existing conditioning approaches. Even so, they are consistent with a platform that is doing something biologically meaningful in a population with substantial relapse risk.
The report leaves transplant oncologists with a clear development trade-off. Alpha-emitting 211At-CD45 can be incorporated into nonmyeloablative conditioning, and it appears capable of producing rapid cytoreduction without obvious delay in engraftment or excess graft-versus-host disease. Yet liver toxicity defines the activity boundary, and the presence of VOD/SOS at the upper end of dose escalation, plus the clustering of cases among patients receiving sirolimus with unrelated donor grafts, will shape how the next trial is designed.
For now, the most defensible interpretation is cautious and concrete: the regimen has entered human testing with real antitumor activity, but the hepatic toxicity profile must be managed before broader use is justified. A phase II study can now test whether this radiobiologic intensification improves relapse control in a way that outweighs the liver risk in a larger and more uniform transplant population.